THE Therapeutic Goods Administration says it has not identified any quality issues in samples of teething gels, after undertaking testing following an alert issued by the US Food and Drug Administration (PD 20 Oct).
While the FDA this week issued a formal warning about elevated and inconsistent levels of belladonna in some homeopathic teething gels sold in the USA (PD Mon), the TGA found that "levels of atropine, the primary alkaloid present in belladonna, were found to be well below the cut-off for this type of product of 300 parts per billion.
"Based on these results no further regulatory action will be taken," the TGA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 17